STAAR Surgical to Report Third Quarter Results on October 30, 2024
Event:
Date:
Time:
Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB
STAAR will also host an earnings webcast on
A replay of the webcast will be available on
About
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241023428313/en/
Investors & Media
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com
Investors –
Director, Investor Relations and Corporate Development –
+852-6092-5076
nliu@staar.com
Source: